Market Expertz have recently published a new report on the global Stem Cell Assay market. The study provides profound insights into updated market events and market trends.
Market Expertz have recently published a new report on the global Stem Cell Assay market. The study provides profound insights into updated market events and market trends.
COVID-19 has dominated the news, and for good reason.
More than 200,000 people have died from COVID-19 since January 2020. While Australia has been relatively spared from the onslaught of infections and deaths, our nations scientists need to be part of the global effort to address this pandemic. Research Group Head, Amnion Cell Biology There is no effective treatment to address the ongoing damage caused by for severe COVID-19 infections, said Associate Professor Rebecca Lim, Research Group Head of Amnion Cell Biology at Hudson Institute.
Campus News The Chancellor Charles P.
Release Date: May 5, 2020 BUFFALO, N.Y.
Members of the research team at the Abu Dhabi Stem Cell Center, United Arab Emirates. Image Credit: WAM / Gulf News DUBAI: Adult stem cell therapy is dubbed as the new healing force of the 21st century, much as theinternet revolutionised the past century. Now, UAE researchers have demonstrated they're in the leading edge of this breakthrough in medicine.
Earlier, treating orthopedic problems just led to temporary cure but not the root cause of the problem. However, the case is not the same now. With emerging research and experience, Dr
Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age? Aging is an inevitable process.
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) and University Hospitals Cleveland Medical Center (UH Cleveland) announced today that UH Cleveland is now open as the first clinical site for the MACOVIA (MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome) trial. On April 13, 2020, Athersys announced authorization from the U.S
DetailsCategory: AntibodiesPublished on Saturday, 02 May 2020 12:42Hits: 411 - Innovative, fixed-dose formulation significantly reduces treatment time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to DARZALEX (daratumumab) for approved indications - DARZALEX FASPRO is the only subcutaneous CD38-directed antibody approved in the treatment of multiple myeloma HORSHAM, PA, USA I May 1, 2020 I The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. DARZALEX FASPRO is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.As a fixed-dose formulation, DARZALEX FASPRO can be administered over approximately three to five minutes, significantly less time than DARZALEX,which is given intravenously over hours
Recent Comments